Zydus Lifesciences Signs $20 Million Sri Lanka Pharma Deal; Shares Rise 0.37%

Mumbai, October 15: Shares of Zydus Lifesciences Ltd rose 0.37% to ₹1,128.90 on Thursday after the company announced an agreement to establish a pharmaceutical manufacturing facility in Sri Lanka with an investment of over $20 million.

The agreement was signed on October 13, 2026, between the Board of Investment of Sri Lanka and the proposed joint venture between Zydus Lifesciences (Pvt) Ltd and Sunshine Healthcare Lanka Ltd, part of Sunshine Holdings PLC.

Zydus Lifesciences Plans Pharmaceutical Manufacturing Facility in Sri Lanka

The facility will be developed across nearly four acres in the Board of Investment zone in Horana, Sri Lanka. Commercial operations are expected to begin in 2028, subject to project timelines and the required regulatory approvals.

In the first phase, the plant will manufacture oral solid dosage forms for the Sri Lankan market. The investment is expected to support Zydus’ international expansion and strengthen the local supply of essential medicines.

Local manufacturing could also improve supply chain resilience and help ensure the availability of essential medicines across Sri Lanka.

Stock Market Snapshot

The Zydus Lifesciences share price was trading 0.37% higher at ₹1,128.90 on Thursday, October 15, 2026, compared with the previous close of ₹1,124.70. The stock opened at ₹1,121.00.

The Sri Lanka project expands Zydus Lifesciences’ manufacturing presence beyond its existing markets. Its progress will depend on project execution, regulatory approvals and the planned commencement of commercial operations in 2028.

About Zydus Lifesciences

Zydus Lifesciences Ltd is an Indian pharmaceutical company engaged in developing and manufacturing medicines and healthcare products. The company operates in domestic and international markets, with a focus on expanding access to healthcare solutions.

Conclusion

Zydus Lifesciences’ agreement to invest over $20 million in a Sri Lankan pharmaceutical facility marks a step in its international expansion strategy. With operations targeted for 2028, the project aims to support local medicine production and strengthen supply chain resilience, subject to regulatory approvals and implementation timelines.

Source:

• https://www.nseindia.com/get-quote/equity/ZYDUSLIFE/Zydus-Lifesciences-Limited
• https://nsearchives.nseindia.com/corporate/Cadilahc_15102026113006_PressRelease15102026.pdf